<DOC>
	<DOC>NCT00925730</DOC>
	<brief_summary>This study will access the degree to which pimecrolimus is absorbed from pimecrolimus cream 1% into the blood when applied repeatedly under occlusion (i.e. areas treated wrapped in a plastic film) over 8 days in patients with moderate to severe atopic eczema.</brief_summary>
	<brief_title>Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patients 2 18 years of age Patients with a diagnosis of moderate to severe atopic dermatitis, assessed by a score â‰¥ 3 at the Investigator's Global Assessment. AD to involve at least 30% of their body surface area as determined by the rule of nine or the Lund and Browder chart. Erythrodermic patients with Netherton's syndrome Patients with known serious adverse reactions or hypersensitivity to any of the excipients of the study medication Patients with a history of cancer, skin malignancy or lymphoproliferative disorders or of immunocompromise, including a positive HIV (ELISA and Western blot), Hepatitis B surface antigen (HBsAg) or Hepatitis C test result Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Atopic dermatitis</keyword>
	<keyword>AD</keyword>
	<keyword>pimecrolimus</keyword>
	<keyword>blood</keyword>
	<keyword>absorption</keyword>
	<keyword>systemic</keyword>
</DOC>